O-I Glass Announces Full Year and Fourth Quarter 2021 Earnings Conference Call and Webcast

Written by Customer Service on January 5, 2022. Posted in Public Companies.

PERRYSBURG, Ohio, Jan. 05, 2022 (GLOBE NEWSWIRE) — FOR IMMEDIATE RELEASE O-I Glass, Inc. (NYSE: OI) has scheduled its full year and fourth quarter 2021 conference call and webcast for Wednesday, February 2, 2022, at 8 a.m. EST. The Company’s news release for the full year and fourth quarter 2021 earnings will be issued after the market closes on Tuesday, February 1. What: O-I Conference Call and WebcastEarnings presentation materials will also be posted on the O-I website, www.o-i.com/investors, when the earnings news release is issued. When: Wednesday, February 2, 2022, at 8 a.m. EST Where: http://investors.o-i.com/webcasts-presentations?c=88324&p=irol-calendar The webcast will be archived at www.o-i.com/investors until February 2023. To participate in the event via conference call, dial 1-888-733-1701...

American Assets Trust, Inc. Increases Revolving Line of Credit to $400 Million and Extends Maturity Date in Its Third Amended and Restated Credit Agreement

Written by Customer Service on January 5, 2022. Posted in Public Companies.

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) — American Assets Trust, Inc. (NYSE:AAT) (the “Company”) announced today that it has amended and restated its existing credit agreement. The credit agreement was amended and restated to, among other things, (1) increase the revolving line of credit from $350 million to $400 million, (2) extend the maturity date of the restated $400 million revolving line of credit to January 5, 2026 (with two, six-month extension options), (3) extend the maturity date of the $100 million term loan included as part of the credit agreement to January 5, 2027 (with no further extension options), (4) decrease the applicable ratings-based pricing spreads and (5) transition borrowings to the Secured Overnight Financing Rate (SOFR), and away from LIBOR. The revolving line of credit and $100 million term loan are...

Richardson Electronics Reports Second Quarter Fiscal 2022 Net Income Of $4.1 Million And Declares Quarterly Cash Dividend

Written by Customer Service on January 5, 2022. Posted in Earnings Releases And Operating Results.

PMT, Canvys and Healthcare Revenues Grow Versus Second Quarter FY21 Second Quarter Highlights Net sales of $54.0 million were up 27.3% from last year’s second quarter. Sales increased for PMG, Canvys, Healthcare and Semiconductor Wafer Fabrication Equipment products in the second quarter of fiscal 2022 versus the second quarter of fiscal 2021. Backlog increased to $146.9 million in the second quarter versus $126.5 million at the end of the first quarter. Gross margin was 32.7% of net sales for the second quarter of fiscal 2022 versus 33.8% of net sales in the prior year’s second quarter primarily due to product mix and higher global freight costs. Operating expenses decreased $0.4 million to $13.1 million compared to the prior year’s second quarter. This decrease was due to lower legal fees, partially offset by increased employee compensation...

CTO Realty Growth Announces Record 2021 Transaction Activity

Written by Customer Service on January 5, 2022. Posted in Mergers And Acquisitions.

WINTER PARK, Fla., Jan. 05, 2022 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced its record 2021 acquisition and disposition activities. 2021 Acquisition Highlights During the year ended December 31, 2021, the Company acquired eight mixed use or retail income properties for total acquisition volume of $249.1 million, representing a weighted-average going-in cash cap rate of 7.2%. The 2021 acquisitions are in well-located submarkets of the high-growth markets of Las Vegas, Nevada; Salt Lake City, Utah; Dallas, Texas; Raleigh, North Carolina; Santa Fe, New Mexico; Orlando, Florida; and Atlanta, Georgia. Notable new tenants in the Company’s portfolio include Sprouts, Burlington, At Home, TJ Maxx, HomeGoods, Synovus, Ross Dress for Less, Season’s 52, WeWork, Dick’s Sporting Goods and...

Saratoga Investment Corp. Announces Fiscal Third Quarter 2022 Financial Results

Written by Customer Service on January 5, 2022. Posted in Earnings Releases And Operating Results.

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE:SAR) (“Saratoga Investment” or “the Company”), a business development company (“BDC”), today announced financial results for its 2022 fiscal third quarter. Summary Financial Information The Company’s summarized financial information is as follows: For the quarterended and as ofNov 30, 2021 For the quarterended and as ofAug 31, 2021 For the quarterended and as ofNov 30, 2020 ($ in thousands except per share) AUM 661,793 666,097 546,944 NAV 324,602 324,112 299,853 NAV per share 29.17 28.97 26.84 Investment Income 16,502 18,442 14,283 Net Investment Income per share 0.45 0.57 0.40 Adjusted Net Investment Income per share 0.53 0.63 0.50 Earnings per share 0.73 0.71 0.57 Dividends per share (declared) 0.53 0.52 0.42 Return...

Landec Corporation Reports Second Quarter Fiscal Year 2022 Results

Written by Customer Service on January 5, 2022. Posted in Earnings Releases And Operating Results.

Reiterates Fiscal 2022 Guidance for Lifecore Provides Pro Forma Curation Foods Segment Results and Updates Guidance for Continuing Segment Operations SANTA MARIA, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) — Landec Corporation (Nasdaq: LNDC) (“Landec” or the “Company”), a diversified health and wellness company with two operating businesses, Lifecore Biomedical, Inc. (“Lifecore”) and Curation Foods, Inc., reported results for the fiscal 2022 second quarter ended November 28, 2021. Subsequent to fiscal second quarter end, on December 13, 2021 the Company closed on the sale of its Curation Food’s fresh packaged salads and vegetables business (the “Eat Smart Disposition”) for $73.5 million in cash, subject to certain adjustments. Looking forward, Landec continues to focus on creating shareholder value through strengthening...

Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022

Written by Customer Service on January 5, 2022. Posted in Public Companies.

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced that the company is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET. A live audio webcast of Intellia’s presentation can be accessed under the Events and Presentations page of the Investors & Media section on the company’s website at www.intelliatx.com. A replay of the audio webcast will be available on Intellia’s website for at least two weeks following the presentation. About Intellia TherapeuticsIntellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative...

Context Therapeutics® Strengthens Research & Development Team

Written by Customer Service on January 5, 2022. Posted in Public Companies.

Company names Christopher Beck as SVP, Operations and Mark Fletcher, Ph.D., as VP, R&D PHILADELPHIA, Jan. 05, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D. Context also announced the planned retirement of its current Head of CMC, Bill Rencher, Ph.D., who will move into an advisory role with the Company. “Context is in a pivotal phase of growth and change as we near key inflection points with our pipeline, bolstered by our recent private placement and initial public offering. As part of Context’s leadership, Mr. Beck and Dr. Fletcher will help...

NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board

Written by Customer Service on January 5, 2022. Posted in Public Companies.

GAITHERSBURG, Md., Jan. 05, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB). The AI & ID SAB is comprised of distinguished academic and industry leaders in the fields of autoimmune and infectious diseases, translational research, immunology and T cell biology. “As we continue to advance our AIM nanotechnology platform, we are grateful to have the input and guidance of these established experts,” said Jerry Zeldis, NexImmune’s EVP of R&D. “Their combined experience in autoimmune and infectious diseases, translational...

CBTX, Inc. Announces Date of Fourth Quarter 2021 Financial Results Conference Call

Written by Customer Service on January 5, 2022. Posted in Public Companies.

HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) — CBTX, Inc., or the Company (NASDAQ: CBTX), the bank holding company for CommunityBank of Texas, N.A., or the Bank, today announced it will hold a quarterly conference call to discuss fourth quarter 2021 financial results on Friday, January 28, 2022 at 8:00 a.m. Central Time (9:00 a.m. Eastern Time). To access the live webcast of the conference call, individuals can visit the Investor Relations page of the Company’s website: https://ir.cbtxinc.com/events-and-presentations. An archived edition of the earnings webcast will also be posted on the Company’s website and will remain available to interested parties via the same link for one year. The conference call can also be accessed by dialing (877) 620-1733 if calling from the U.S. or Canada (or (470) 414-9785 if calling from outside the U.S.)....

Day: January 5, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice